Table 4.
Literature review of SBRT for cholangiocarcinoma
| Reference | Year | Patients (n) | Total Dose (Gy) | Fractions | 12-month LC (%) | Median OS (months) | Comments |
|---|---|---|---|---|---|---|---|
| Herfarth et al. [13] |
2001 |
3 |
14 - 26 |
1 |
71 |
NR |
Target volume covered by 80% isodose |
| Tse et al. [16] |
2008 |
10 |
32.5 |
6 |
65 |
15 |
Hypofractionated stereotactic radiotherapy |
| Goodman et al. [12] |
2010 |
5 |
18 - 30 |
1 |
77 |
29 |
Single-fraction dose escalation study |
| Kopek et al. [14] |
2010 |
27 |
45 |
3 |
NR |
11 |
22% rate of serious GI injury |
| Polistina et al. [15] |
2011 |
10 |
30 |
3 |
NR |
36 |
All patients received concurrent gemcitabine |
| Current Study | 2012 | 10 | 55 | 5 | 100 | 14 | Includes both recurrent and metastatic lesions |
Abbreviations: LC Local control, OS Overall survival, NR Not reported, GI Gastrointestinal.